 NEW YORK, March 10, 2022 GLOBE NEWSWIRE -- Cognition Therapeutics , Inc. NASDAQ: CGTX, a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 σ-2 receptor modulator in development for Alzheimers disease and other neurodegenerative disorders. Specifically, data will be presented from the Phase 1b SNAP study COG0104; NCT03522129 and an interim analysis from the Phase 2 SHINE study COG0201; NCT03507790 in two posters at the upcoming ADPDTM 2022: the 16th International Conference on Alzheimers Parkinsons Diseases. 